Compare SGC & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGC | ACIU |
|---|---|---|
| Founded | 1920 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.8M | 229.7M |
| IPO Year | 1994 | 2015 |
| Metric | SGC | ACIU |
|---|---|---|
| Price | $13.61 | $2.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $18.00 | $8.70 |
| AVG Volume (30 Days) | 22.6K | ★ 191.9K |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $566,184,000.00 | N/A |
| Revenue This Year | $3.02 | $422.39 |
| Revenue Next Year | $3.83 | $377.85 |
| P/E Ratio | $100.57 | ★ N/A |
| Revenue Growth | ★ 0.09 | N/A |
| 52 Week Low | $8.30 | $2.02 |
| 52 Week High | $14.59 | $3.90 |
| Indicator | SGC | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 64.98 | 44.60 |
| Support Level | $11.52 | $2.13 |
| Resistance Level | $14.57 | $2.47 |
| Average True Range (ATR) | 0.52 | 0.14 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 100.00 | 53.92 |
Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.